Sage Therapeutics, Inc. (NASDAQ:SAGE) Research Coverage Started at Stifel Nicolaus

Analysts at Stifel Nicolaus initiated coverage on shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) in a note issued to investors on Wednesday, August 9th, Marketbeat reports. The brokerage set a “buy” rating and a $104.00 price target on the biopharmaceutical company’s stock. Stifel Nicolaus’ price target suggests a potential upside of 28.59% from the company’s previous close.

Several other equities analysts have also issued reports on SAGE. Needham & Company LLC set a $95.00 price target on Sage Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 4th. Cowen and Company reiterated a “buy” rating and issued a $100.00 price objective on shares of Sage Therapeutics in a research report on Friday, August 4th. HC Wainwright lifted their price objective on Sage Therapeutics to $86.00 and gave the stock a “neutral” rating in a research report on Friday, August 4th. BidaskClub lowered Sage Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Canaccord Genuity set a $110.00 price objective on Sage Therapeutics and gave the stock a “buy” rating in a research report on Saturday, August 5th. Four research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company’s stock. Sage Therapeutics currently has an average rating of “Buy” and an average target price of $89.64.

Sage Therapeutics (SAGE) opened at 80.88 on Wednesday. Sage Therapeutics has a 52-week low of $36.01 and a 52-week high of $90.43. The stock’s market capitalization is $3.03 billion. The stock has a 50 day moving average of $82.25 and a 200 day moving average of $71.41.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by $0.25. During the same period last year, the company posted ($1.08) earnings per share. On average, equities research analysts forecast that Sage Therapeutics will post ($7.38) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Sage Therapeutics, Inc. (NASDAQ:SAGE) Research Coverage Started at Stifel Nicolaus” was first posted by BNB Daily and is the sole property of of BNB Daily. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.baseball-news-blog.com/2017/08/19/sage-therapeutics-inc-nasdaqsage-now-covered-by-analysts-at-stifel-nicolaus-updated.html.

Several hedge funds have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd raised its stake in shares of Sage Therapeutics by 164.4% in the second quarter. Dynamic Technology Lab Private Ltd now owns 7,513 shares of the biopharmaceutical company’s stock valued at $598,000 after buying an additional 4,671 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Sage Therapeutics by 19.6% in the second quarter. Ameritas Investment Partners Inc. now owns 3,034 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 497 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Sage Therapeutics by 3.2% in the second quarter. California State Teachers Retirement System now owns 61,252 shares of the biopharmaceutical company’s stock valued at $4,878,000 after buying an additional 1,910 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in shares of Sage Therapeutics by 41.0% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 8,682 shares of the biopharmaceutical company’s stock valued at $691,000 after buying an additional 2,525 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Sage Therapeutics by 13.5% in the second quarter. The Manufacturers Life Insurance Company now owns 26,980 shares of the biopharmaceutical company’s stock valued at $2,149,000 after buying an additional 3,216 shares during the last quarter.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply